Immunai

Executive Summary

Immunai is an AI-driven biotechnology company headquartered in Tel Aviv, Israel, that leverages single-cell multi-omics and machine learning to decode the human immune system. Its proprietary AMICA atlas and wet-lab sequencing capabilities provide actionable insights for drug discovery, target validation, and clinical trial design in oncology, immunology, and inflammatory diseases. Founded in 2020, the company has raised $45 million and operates as a platform-stage private entity. Immunai's technology addresses a critical bottleneck in immunology by enabling high-resolution, data-driven decision-making, potentially reducing drug development timelines and costs. However, the company faces competition from other AI-based immune profiling platforms and must demonstrate robust commercial adoption and clinical utility to secure follow-on funding and partnerships.

Upcoming Catalysts (preview)

• Q1 2027Announcement of a major pharmaceutical partnership65% success
• Q4 2026Publication of validation data in a peer-reviewed journal75% success
• Q2 2027Series B or Series C funding round50% success